The role of azacitidine in the treatment of elderly patients with acute myeloid leukemia: Results of a retrospective multicenter study [Akut miyeloid lösemili yaşlı hastaların tedavisinde azasitidinin rolü: Retrospektif çok merkezli bir çalışmanın sonuçları]

Basit Öğe Kaydı
dc.contributor.authorTombak A.
dc.contributor.authorUçar M.A.
dc.contributor.authorAkdeniz A.
dc.contributor.authorTiftik E.N.
dc.contributor.authorŞahin D.G.
dc.contributor.authorAkay O.M.
dc.contributor.authorYıldırım M.
dc.contributor.authorNevruz O.
dc.contributor.authorKis C.
dc.contributor.authorGürkan E.
dc.contributor.authorSolmaz Ş.M.
dc.contributor.authorÖzcan M.A.
dc.contributor.authorYıldırım R.
dc.contributor.authorBerber İ.
dc.contributor.authorErkurt M.A.
dc.contributor.authorTuğlular T.F.
dc.contributor.authorTarkun P.
dc.contributor.authorYavaşoğlu İ.
dc.contributor.authorDoğu M.H.
dc.contributor.authorSarı İ.
dc.contributor.authorMerter M.
dc.contributor.authorÖzcan M.
dc.contributor.authorYıldızhan E.
dc.contributor.authorKaynar L.
dc.contributor.authorMehtap Ö.
dc.contributor.authorUysal A.
dc.contributor.authorŞahin F.
dc.contributor.authorSalim O.
dc.contributor.authorSungur M.A.
dc.date.accessioned2019-10-27T08:21:00Z
dc.date.available2019-10-27T08:21:00Z
dc.date.issued2016
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: In this study, we aimed to investigate the efficacy and safety of azacitidine (AZA) in elderly patients with acute myeloid leukemia (AML), including patients with >30% bone marrow (BM) blasts. Materials and Methods: In this retrospective multicenter study, 130 patients of ?60 years old who were ineligible for intensive chemotherapy or had progressed despite conventional treatment were included. Results: The median age was 73 years and 61.5% of patients had >30% BM blasts. Patients received AZA for a median of four cycles (range: 1-21). Initial overall response [including complete remission (CR)/CR with incomplete recovery/partial remission] was 36.2%. Hematologic improvement (HI) of any kind was documented in 37.7% of all patients. HI was also documented in 27.1% of patients who were unresponsive to treatment. Median overall survival (OS) was 18 months for responders and 12 months for nonresponders (p=0.005). In the unresponsive patient group, any HI improved OS compared to patients without any HI (median OS was 14 months versus 10 months, p=0.068). Eastern Cooperative Oncology Group performance status of <2, increasing number of AZA cycles (?5 courses), and any HI predicted better OS. Age, AML type, and BM blast percentage had no impact. Conclusion: We conclude that AZA is effective and well tolerated in elderly comorbid AML patients, irrespective of BM blast count, and HI should be considered a sufficient response to continue treatment with AZA. © 2016, Turkish Society of Hematology. All rights reserved.en_US
dc.identifier.doi10.4274/tjh.2015.0203en_US
dc.identifier.endpage280en_US
dc.identifier.issn1300-7777
dc.identifier.issue4en_US
dc.identifier.pmid27095141en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage273en_US
dc.identifier.urihttps://doi.org/10.4274/tjh.2015.0203
dc.identifier.urihttps://hdl.handle.net/11454/25886
dc.identifier.volume33en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTurkish Society of Hematologyen_US
dc.relation.ispartofTurkish Journal of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAcute myeloid leukemiaen_US
dc.subjectAzacitidineen_US
dc.subjectBone marrow blastsen_US
dc.subjectElderlyen_US
dc.subjectOverall survivalen_US
dc.subjectPrognostic factorsen_US
dc.titleThe role of azacitidine in the treatment of elderly patients with acute myeloid leukemia: Results of a retrospective multicenter study [Akut miyeloid lösemili yaşlı hastaların tedavisinde azasitidinin rolü: Retrospektif çok merkezli bir çalışmanın sonuçları]en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu